Skip to main content
. 2012 May 15;18(1):1009–1017. doi: 10.2119/molmed.2012.00173

Figure 1.

Figure 1

LXR and the LXR-inducible gene SCD1 are expressed in FLS. (A) LXRα and LXRβ expression in RA fibroblast–like synoviocytes is reduced by IL-1β (10 ng/mL) treatment. Pre-treatment with the LXR agonist T0901317 (10 μmol/L) prevented the IL-1β–induced reduction of LXRα (four FLS cell lines from different RA patients). Levels of LXRβ were not significantly affected by IL-1β treatment. (B) Levels of the LXR-inducible gene SCD1 were low at baseline and were not affected by IL-1β treatment. Pretreatment with the LXR agonist T0901317 significantly increased the expression of SCD1 by 26-fold, demonstrating that LXR is responsive to the synthetic agonist (#P = 0.0014, t test; n = 7). (C) Western blot showing that both LXRα and LXRβ proteins are expressed in FLS, but levels are not changed by IL-1β treatment in the presence or absence of T0901317 during 24-h and 72-h periods. Vinculin was used as the loading control for protein normalization (representative of experiments done with five different DA FLS cell lines). No stim, no stimulation.